ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
First Patient Dosed in STP705 Study Cutaneous Basal Cell Carcinoma Treatment
January 27, 2021Sirnaomics announced dose administration for the first patient in a Phase 2a clinical study of the company's lead drug candidate, STP705, for the treatment of cutaneous basal cell carcinoma. -
Sirnaomics Receives FDA Clearance to Initiate Phase 2 Study of STP705
December 21, 2018Sirnaomics announced the U.S. Food and Drug Administration (FDA) has agreed to the company's proposed trial design for a Phase 2 clinical study to .....
Pharma Sources Insight January 2025
